Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -2.76% is 84% above its 5-year average of -17.50%, near the high end of its 5-year range (-54.22%–1.44%).
As of the fiscal period ended Tuesday, June 30, 2026. 83.23% above its 12-month average of -16.43%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -2.76%.
RETURN ON EQUITY (ROE)
-2.76%
RETURN ON EQUITY (ROE) AVG TTM
-16.43%
RETURN ON EQUITY (ROE) AVG 3Y
-26.11%
RETURN ON EQUITY (ROE) AVG 5Y
-17.50%
RETURN ON EQUITY (ROE) AVG 10Y
1.28%
RETURN ON EQUITY (ROE) AVG 15Y
6.63%
RETURN ON EQUITY (ROE) AVG 20Y
7.30%
CURRENT VS TTM AVG
+83.23%
CURRENT VS 3Y AVG
+89.44%
CURRENT VS 5Y AVG
+84.25%
CURRENT VS 10Y AVG
-315.17%
CURRENT VS 15Y AVG
-141.55%
CURRENT VS 20Y AVG
-137.75%
SECTOR MEDIAN · HEALTHCARE
-37.94%
median of 451 covered companies
CURRENT VS SECTOR MEDIAN
+92.73%
vs the sector median at left
Anika Therapeutics, Inc.
Market Cap
$264.05M
Return on Equity (ROE)
-2.76%
TTM Avg
-16.43%
3Y Avg
-26.11%
5Y Avg
-17.50%
Market Cap
$261.48M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
Market Cap
$266.62M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
Market Cap
$260.11M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
Market Cap
$269.80M
Return on Equity (ROE)
-47.25%
TTM Avg
-42.23%
3Y Avg
-50.43%
5Y Avg
-29.25%
Market Cap
$251.01M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$272.75M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
Market Cap
$251.06M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
Market Cap
$249.82M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $264.05M | -2.76% | -16.43% | -26.11% | -17.50% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.48M | -38.33% | -61.68% | -393.03% | -278.88% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.62M | -184.27% | -57.34% | -61.84% | -87.31% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $260.11M | -39.55% | -28.46% | -79.02% | -63.95% |
| Century Therapeutics, Inc. (IPSC)vs › | $269.80M | -47.25% | -42.23% | -50.43% | -29.25% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.01M | N/A | -125.28% | -42.20% | -43.41% |
| AC Immune S.A. (ACIU)vs › | $272.75M | -124.67% | -101.06% | -69.44% | -56.33% |
| Invivyd, Inc. (IVVD)vs › | $251.06M | -59.27% | -136.66% | -113.26% | -53.68% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.82M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| InflaRx N.V. (IFRX)vs › | $248.92M | -27.27% | -92.43% | -64.95% | -57.80% |
ROE
-2.8%
ROA
-2.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -2.76% |
| 2026-03-31 | -8.26% |
| 2025-12-31 | -7.58% |
| 2025-09-30 | -22.50% |
| 2025-06-30 | -41.05% |
| 2025-03-31 | -38.24% |
| 2024-12-31 | -36.62% |
| 2024-09-30 | -54.22% |
| 2024-06-30 | -35.27% |
| 2024-03-31 | -36.84% |
| 2023-12-31 | -38.95% |
| 2023-09-30 | -9.09% |
| 2023-06-30 | -8.09% |
| 2023-03-31 | -8.02% |
| 2022-12-31 | -5.20% |
| 2022-09-30 | -5.53% |
| 2022-06-30 | -3.85% |
| 2022-03-31 | -0.57% |
| 2021-12-31 | 1.44% |
| 2021-09-30 | -1.98% |
| 2021-06-30 | -4.43% |
| 2021-03-31 | -9.74% |
| 2020-12-31 | -8.80% |
| 2020-09-30 | -1.50% |
| 2020-06-30 | 3.93% |
| 2020-03-31 | 9.70% |
| 2019-12-31 | 9.43% |
| 2019-09-30 | 10.96% |
| 2019-06-30 | 11.66% |
| 2019-03-31 | 11.12% |
| 2018-12-31 | 7.10% |
| 2018-09-30 | 7.47% |
| 2018-06-30 | 7.44% |
| 2018-03-31 | 7.44% |
| 2017-12-31 | 12.07% |
| 2017-09-30 | 12.57% |
| 2017-06-30 | 13.89% |
| 2017-03-31 | 13.54% |
| 2016-12-31 | 14.61% |
| 2016-09-30 | 16.55% |
| 2016-06-30 | 17.09% |
| 2016-03-31 | 17.47% |
| 2015-12-31 | 14.59% |
| 2015-09-30 | 13.78% |
| 2015-06-30 | 13.29% |
| 2015-03-31 | 14.74% |
| 2014-12-31 | 21.52% |
| 2014-09-30 | 21.90% |
| 2014-06-30 | 22.13% |
| 2014-03-31 | 20.78% |
| 2013-12-31 | 15.17% |
| 2013-09-30 | 14.34% |
| 2013-06-30 | 12.62% |
| 2013-03-31 | 11.45% |
| 2012-12-31 | 10.79% |
| 2012-09-30 | 9.84% |
| 2012-06-30 | 11.42% |
| 2012-03-31 | 10.23% |
| 2011-12-31 | 8.93% |
| 2011-09-30 | 7.47% |
| 2011-06-30 | 5.64% |
| 2011-03-31 | 4.48% |
| 2010-12-31 | 5.07% |
| 2010-09-30 | 4.34% |
| 2010-06-30 | 5.00% |
| 2010-03-31 | 4.77% |
| 2009-12-31 | 4.49% |
| 2009-09-30 | 6.35% |
| 2009-06-30 | 5.88% |
| 2009-03-31 | 5.76% |
| 2008-12-31 | 5.97% |
| 2008-09-30 | 7.10% |
| 2008-06-30 | 8.48% |
| 2008-03-31 | 9.65% |
| 2007-12-31 | 10.98% |
| 2007-09-30 | 10.28% |
| 2007-06-30 | 9.81% |
| 2007-03-31 | 10.36% |
| 2006-12-31 | 10.12% |
| 2006-09-30 | 9.97% |
| 2006-06-30 | 13.41% |
| 2006-03-31 | 14.03% |
| 2005-12-31 | 15.55% |
| 2005-09-30 | 18.42% |
| 2005-06-30 | 15.01% |
| 2005-03-31 | 14.47% |
| 2004-12-31 | 36.85% |
| 2004-09-30 | 36.71% |
| 2004-06-30 | 36.42% |
| 2004-03-31 | 34.63% |
| 2003-12-31 | 4.60% |
| 2003-09-30 | 3.99% |
| 2003-06-30 | -2.83% |
